Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Charles River Laboratories Completes Acquisition of Majority Ownership of Vital River

Published: Tuesday, January 08, 2013
Last Updated: Tuesday, January 08, 2013
Bookmark and Share
Charles River Laboratories International, Inc. takes 75% ownership of Vital River, the premier commercial provider of research models and related services in China, and a licensee of Charles River for the last ten years.

James C. Foster, Chairman, President, and Chief Executive Officer of Charles River Laboratories, commented, “Through this acquisition, Charles River will provide high-quality research models and associated services to the emerging China market for drug discovery and development. We expect demand for research models in China to significantly increase over the next several years as drug development initiatives in academia, government and biopharmaceutical companies expand. Charles River intends to set the standards for research models in China, the third-largest pharmaceutical market in the world, and play a leading role in this emerging opportunity.”

As part of the Vital River acquisition, Charles River will be the exclusive global partner for distribution of model creation services offered through Beijing Vital Star Biotechnology. The services of Beijing Vital Star Biotechnology include humanized model creation utilizing inducible pluripotent stem cell (iPS) and other technologies.

Charles River acquired the 75% ownership of Vital River for approximately $27 million, subject to certain post-closing working capital adjustments. The transaction is expected to add more than 1% to 2013 total net sales and be slightly accretive to 2013 earnings per share.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Charles River Laboratories to Acquire WIL Research
Enhances Charles River’s position as a leading global early-stage CRO.
Thursday, January 14, 2016
Charles River to Acquire WIL Research
Enhances Charles River’s position as a leading global early-stage CRO.
Friday, January 08, 2016
CRL Expands Long-Standing Collaboration with MJFF
Advanced efforts to identify novel small molecule LRRK2 inhibitors.
Tuesday, December 15, 2015
Charles River Laboratories Acquires Oncotest GmbH
Expands oncology capabilities of Charles River discovery services.
Thursday, November 26, 2015
Charles River Announces New and Continued Drug Discovery Collaborations
Wellcome Trust-funded projects expand partnerships with Charles River’s Global Discovery Services business.
Friday, October 09, 2015
Charles River Laboratories to Acquire Celsis International
Enhances Charles River Endotoxin and Microbial Detection’s position as the most comprehensive solution for rapid quality control testing.
Thursday, July 16, 2015
Charles River Acquires ChanTest
Addition broadens Charles Rivers' existing discovery-focused ion channel capabilities.
Friday, October 31, 2014
Charles River Laboratories Completes Acquisition of Galapagos’ CRO Services
Acquisition is expected to add approximately 6% to Company’s net sales in 2014.
Thursday, April 03, 2014
Charles River to Acquire Argenta and BioFocus from Galapagos
Capabilities of companies' more than 340 scientists will augment Charles River’s position.
Thursday, March 13, 2014
Charles River Laboratories Announces First-Quarter 2013 Results from Continuing Operations
First-quarter sales of $291.2 million.
Thursday, May 02, 2013
Charles River Laboratories Enters Strategic Partnership with AstraZeneca
Global CRO partners with global biopharmaceutical company to accelerate drug development.
Friday, October 19, 2012
Charles River Announces Second-Quarter 2012 Results from Continuing Operations
Second-quarter sales of $284.7 million.
Thursday, August 09, 2012
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!